<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-041372</identifier>
<setSpec>0212-6567</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Metformin for type 2 diabetes mellitus. Systematic review and meta-analysis</dc:title>
<dc:description xml:lang="en">Objective. To evaluate the efficacy of metformin against placebo, diet, oral anti-diabetics, or insulin in type 2 diabetes mellitus. Design. Systematic review. Data sources. MEDLINE (1966-2003), EMBASE (1974-2003), LILACS (1986-2003), Cochrane library (Issue 3, 2003). Selection of studies. 29 randomized clinical trials of metformin in monotherapy, with results on mortality, morbility, and biochemistry. Extraction of data. RevMan 4 computer program. Two reviewers extracted the data and evaluated the quality. Main variables: any clinical event related to diabetes (mortality, coronary disease, stroke, arterial disease, and retinopathy). Secondary variables: weight and biochemistry. Results. 29 clinical studies with 37 comparisons of metformin were analyzed (13 with sulphonylureas, 12 with placebo, 3 with diet, 3 with thiazolidinediones, 2 with alpha-glucosidase inhibitors, 2 with insulin, and 2 with meglitinides). Metformin was more beneficial than the sulphonylureas or insulin for any clinical event associated with diabetes (relative risk [RR]=0.78; 95% confidence interval [CI], 0.65-0.94) and than diet (RR=0.74; 95% CI, 0.60-0,90). Metformin decreased glycosylated hemoglobin A1 (weighted mean difference, ­1.21%; 95% CI, ­1.48 to ­0.94), low density lipoprotein cholesterol (weighted mean difference, ­0.24; 95% CI, ­0.40 to ­0.09), and weight (standardized mean difference, ­0.11; 95% CI, ­0.18 to ­0.04). Metformin was more beneficial than the placebo, diet or the thiazolidinediones on glycosylated hemoglobin A1, and than the sulphonylureas or insulin on weight. Conclusions. In the long term metformin reduces the risks of clinical events associated with diabetes. There are no long term clinical trials which compare alpha-glucosidase inhibitors, meglitinides, and thiazolidinediones with metformin, in primary results. The different treatments compared with metformin did not obtain more benefit for the secondary results evaluated</dc:description>
<dc:creator>Sáenz Calvo, A</dc:creator>
<dc:creator>Roqué, M</dc:creator>
<dc:creator>Fernández Esteban, I</dc:creator>
<dc:creator>Moher, D</dc:creator>
<dc:creator>Ausejo Segura, M</dc:creator>
<dc:creator>Mataix Sanjuán, A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo. Evaluar la eficacia de la metformina frente a placebo, dieta, antidiabéticos orales o insulina en la diabetes mellitus tipo 2. Diseño. Revisión sistemática. Fuentes de datos. MEDLINE (1966-2003), EMBASE (1974-2003), LILACS (1986- 2003), Cochrane library (Issue 3, 2003). Selección de estudios. Se seleccionaron 29 ensayos clínicos aleatorizados de metformina en monoterapia, con resultados sobre mortalidad, morbilidad y bioquímica. Extracción de datos. Programa informático RevMan 4. Dos revisores extrajeron los datos y evaluaron la calidad. Variables principales: cualquier acontecimiento clínico relacionado con la diabetes (mortalidad, coronariopatía, ictus, nefropatía, arteriopatía y retinopatía). Variables secundarias: peso y bioquímica. Resultados. Se analizaron 29 ensayos clínicos con 37 comparaciones de metformina (13 con sulfonilureas, 12 con placebo, 3 con dieta, 3 con tiazolidindionas, 2 con inhibidores de la alfa-glucosidasa, 2 con insulina y 2 con meglitinidas). La metformina mostró mayor beneficio que las sulfonilureas o la insulina para cualquier acontecimiento clínico relacionado con la diabetes (riesgo relativo = 0,78; intervalo de confianza [IC] del 95%, 0,65 a 0,94) y que la dieta (riesgo relativo = 0,74; IC del 95%, 0,60 a 0,90). La metformina disminuyó la hemoglobina A1 glucosilada (diferencia media ponderada: ­1,21%; IC del 95%, ­1,48 a ­0,94), colesterol unido a lipoproteínas de baja densidad (diferencia media ponderada: ­0,24; IC del 95%, ­0,40 a ­0,09) y peso (diferencia media estandarizada: ­0,11; IC del 95%, ­0,18 a ­0,04). La metformina presentó mayor beneficio que el placebo, la dieta o las tiazolidindionas en la hemoglobina A1 glucosilada, y que las sulfonilureas o la insulina en el peso. Conclusiones. A largo plazo la metformina disminuye el riesgo de acontecimientos clínicos relacionados con la diabetes. No existen ensayos clínicos a largo plazo que comparen con metformina los inhibidores de la alfa-glucosidasa, meglitinidas y tiazolidindionas, en resultados primarios. Las diferentes intervenciones comparadas con metformina no obtuvieron más beneficio para los resultados secundarios evaluados</dc:description>
<dc:source>Aten Primaria;36(4): 183-191, sept. 2005. ilus, tab</dc:source>
<dc:identifier>ibc-041372</dc:identifier>
<dc:title xml:lang="es">Metformina para la diabetes mellitus tipo 2. Revisión sistemática y metaanálisis</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d3946^s22057</dc:subject>
<dc:subject>^d24560</dc:subject>
<dc:subject>^d3946^s22012</dc:subject>
<dc:subject>^d7182^s22000</dc:subject>
<dc:subject>^d22190^s22002</dc:subject>
<dc:subject>^d3946^s22062</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d24852</dc:subject>
<dc:subject>^d24584</dc:subject>
<dc:subject>^d22780</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d8862^s22073</dc:subject>
<dc:subject>^d7182^s22073</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d8862^s22000</dc:subject>
<dc:subject>^d3946^s22017</dc:subject>
<dc:subject>^d3946^s22047</dc:subject>
<dc:subject>^d11350</dc:subject>
<dc:subject>^d8252^s22062</dc:subject>
<dc:type>article</dc:type>
<dc:date>200509</dc:date>
</metadata>
</record>
</ibecs-document>
